EFFECTOR Therapeutics shares are trading lower by 74% during Monday's session. The company announced that it has terminated its employees and will wind down its operations.
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&P 500 also fell, dropping, 0.28% to 5,197.03.
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P 500 also rose, gaining, 0.75% to 5,250.72.
eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib shows modest activity, but no clear path forward. Zotatifin emerges as a potential candidate for ER+ breast cancer trials.
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 39,259.15 while the NASDAQ rose 0.85% to 16,411.43. The S&P 500 also rose, gaining, 0.67% to 5,246.15.
U.S. stocks traded lower this morning, with the Dow Jones falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.63% to 37,445.51 while the NASDAQ fell 0.66% to 14,745.96. The S&P 500 also fell, dropping, 0.55% to 4,737.17.
Shares of LumiraDx Limited (NASDAQ: LMDX) shares fell sharply in pre-market trading. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th. LumiraDx shares dipped 30.5% to $0.0239 in pre-market trading.
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some other stocks moving in pre-market trading.
eFFECTOR Therapeutics Inc (NASDAQ: EFTR) announced new interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 study of zotatifin in patients with estrogen receptor positive (ER+)
